ERBB2 and breast cancer: The BOLERO-2 trial demonstrated a clinically meaningful improvement in PFS with everolimus plus exemestane therapy in patients with ER–positive/HER2-negative advanced breast cancer [10,11].Despite these encouraging results, not all patients benefit from everolimus, and an optimal target patient population for this drug is yet to be defined.